Latest Epithelial sodium channel Stories
ChanTest’s expertise will be showcased at the North American Cystic Fibrosis Conference this month, highlighting the important research the company has conducted to help move cystic fibrosis
Expanded Collaboration Supports Phase 2 Clinical Trial Initiation of First-In-Class ENaC Inhibitor for the Treatment of Cystic Fibrosis DURHAM, N.C., Sept.
-- Parion has a plan for the first clinical trial in patients with dry eye disease to initiate in July 2014 DURHAM, N.C., June 12, 2014 /PRNewswire/ -- Parion Sciences, Inc.
Staff expanded in preparation for initiation of pulmonary and ophthalmic clinical trials DURHAM, N.C., June 2, 2014 /PRNewswire/ -- Parion Sciences, a company dedicated to the development of
- Initiation of Phase 1/2a clinical trial in subjects with dry eye disease expected mid-2014 DURHAM, N.C., May 1, 2014 /PRNewswire/ -- Parion Sciences, a company dedicated to the
Parion plans to initiate Phase 2 studies of P-1037 for the treatment of cystic fibrosis in the second half of 2014 DURHAM, N.C., April 30, 2014 /PRNewswire/ -- Parion Sciences, a company
A recent study led by Gergely Lukacs, a professor at McGill University's Faculty of Medicine, Department of Physiology, and published in the January issue of Cell, has shown that restoring normal function to the mutant gene product responsible for cystic fibrosis (CF) requires correcting two distinct structural defects.
Maintaining fluid balance in the body is essential to survival, from the tiniest protozoa to the mightiest of mammals.
Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator (CFTR).
- A trick or prank.